Inhibikase (Nasdaq: $IKT) is developing disease-modifying therapeutics for Parkinson's disease to restore functional loss inside & outside of the brain.
Location: United States, Georgia, Vinings
Employees: 1-10
Total raised: $10M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Georgia Re... | gra.org |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.01.2023 | - | $10M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 07.03.2024 | Inhibikase Therapeutics to Provide Trial Update for Risvodet... | - | globenewsw... |
| 23.03.2023 | Inhibikase Therapeutics to Report Fourth Quarter and Full-Ye... | BOSTON and ATLANTA, March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. IKT ("Inhibika... | einpresswi... |
| 16.08.2021 | Inhibikase Therapeutics Reports Second Quarter 2021 Financia... | prnewswire... | |
| 18.06.2021 | Inhibikase Therapeutics Announces Closing of Follow-On Offer... | prnewswire... |